Medical management of lower urinary tract symptoms in men: current treatment and future approaches

Men with lower urinary tract symptoms frequently do not seek medical advice. For those who do, the traditional view of a solely prostatic origin might hinder management, since growing evidence suggests an important role for nonprostatic causes. This Review clarifies terminology for symptoms and caus...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature clinical practice urology 2008-04, Vol.5 (4), p.211-219
Hauptverfasser: Chapple, Christopher R, Patel, Anand K
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 219
container_issue 4
container_start_page 211
container_title Nature clinical practice urology
container_volume 5
creator Chapple, Christopher R
Patel, Anand K
description Men with lower urinary tract symptoms frequently do not seek medical advice. For those who do, the traditional view of a solely prostatic origin might hinder management, since growing evidence suggests an important role for nonprostatic causes. This Review clarifies terminology for symptoms and causes and presents an overview of the available medical therapies. Lower urinary tract symptoms (LUTS) are extremely common in men and, in addition to causing considerable bother, can lead to the development of complications, such as acute urinary retention. Over the past couple of decades, developments in the medical management of LUTS in men have led to a substantial decline in the number of surgical procedures being performed to treat associated disorders, such as prostatectomy for benign prostatic enlargement. In this Review we summarize the available treatments and discuss the latest data on the use of anticholinergics and phosphodiesterase type-5 inhibitors for this indication. We also review the various combinations of medical therapies that have been reported in the literature to optimize the management of LUTS in men. In addition, there is a growing realization that LUTS in men are not synonymous with prostatic disease, and in many patients overactive bladder syndrome is the cause or a component of the LUTS experienced; we have, therefore, taken the opportunity to try to clarify the terminology used in LUTS in men, since there is the potential for considerable confusion with the terms that are currently in common usage in any discussion of this disorder. Key Points Although terminology regarding lower urinary tract symptoms (LUTS) in men and their underlying disorders has evolved, it remains confusing, and terms describing the nature of the LUTS (voiding or storage) might be more appropriate, particularly when the underlying diagnosis is unknown Improved understanding of the role of overactive bladder syndrome and storage symptoms in the etiology of LUTS in men has led to a paradigm shift away from the disorder being equated with prostatic disease or bladder outlet obstruction The aims of medical therapy for LUTS in men should be to improve the bothersome symptoms and/or reduce progression of the disease The availability of effective medical treatments for LUTS has led to a dramatic decline in the number of prostatectomies that are performed Enhanced understanding of the underlying causes of male LUTS has led to an interest in the role of anticholinergics
doi_str_mv 10.1038/ncpuro1060
format Article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_70472334</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A186517763</galeid><sourcerecordid>A186517763</sourcerecordid><originalsourceid>FETCH-LOGICAL-c441t-8b79b9f1e6dd80a4c0c4ed66baef0dd889cdcb36b0b992dab30d1d0e694828e13</originalsourceid><addsrcrecordid>eNptkUtr3DAUhUVpyavZ9AcUQaGLhEkkS7Hk7EJokkJKN-la6HE9dbAlVw9K_n3lzpBMS9BC4uo7R1f3IPSBkjNKmDz3di4xUNKSN-iACs5WvJHd2-ezIPvoMKVHQpgQnO6hfSoZoZyKA2S-gRusHvGkvV7DBD7j0OMx_IaISxy8jk84R20zTk_TnMOU8OBx5S6xLTEufI6g81-l9g73JZcIWM9zDNr-hPQevev1mOB4ux-hHzdfHq7vVvffb79eX92vLOc0r6QRnel6Cq1zkmhuieXg2tZo6Ektyc46a1hriOm6xmnDiKOOQNtx2Uig7Ah93vjWh38VSFlNQ7IwjtpDKEkJwkXDGK_gp__Ax1Cir70pKmQnZXNBdqi1HkENvg_LGBZLdUVle0GFaFmlzl6h6nIwDTZ46Ida_0dwshHYGFKK0Ks5DlOdsqJELXGqlzgr_HHbaTETuBd0m18FTjdAqld-DXHnK6_Z4Q3t9ZLRs90O8gf6Nbai</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1789882504</pqid></control><display><type>article</type><title>Medical management of lower urinary tract symptoms in men: current treatment and future approaches</title><source>MEDLINE</source><source>Nature</source><source>Alma/SFX Local Collection</source><creator>Chapple, Christopher R ; Patel, Anand K</creator><creatorcontrib>Chapple, Christopher R ; Patel, Anand K</creatorcontrib><description>Men with lower urinary tract symptoms frequently do not seek medical advice. For those who do, the traditional view of a solely prostatic origin might hinder management, since growing evidence suggests an important role for nonprostatic causes. This Review clarifies terminology for symptoms and causes and presents an overview of the available medical therapies. Lower urinary tract symptoms (LUTS) are extremely common in men and, in addition to causing considerable bother, can lead to the development of complications, such as acute urinary retention. Over the past couple of decades, developments in the medical management of LUTS in men have led to a substantial decline in the number of surgical procedures being performed to treat associated disorders, such as prostatectomy for benign prostatic enlargement. In this Review we summarize the available treatments and discuss the latest data on the use of anticholinergics and phosphodiesterase type-5 inhibitors for this indication. We also review the various combinations of medical therapies that have been reported in the literature to optimize the management of LUTS in men. In addition, there is a growing realization that LUTS in men are not synonymous with prostatic disease, and in many patients overactive bladder syndrome is the cause or a component of the LUTS experienced; we have, therefore, taken the opportunity to try to clarify the terminology used in LUTS in men, since there is the potential for considerable confusion with the terms that are currently in common usage in any discussion of this disorder. Key Points Although terminology regarding lower urinary tract symptoms (LUTS) in men and their underlying disorders has evolved, it remains confusing, and terms describing the nature of the LUTS (voiding or storage) might be more appropriate, particularly when the underlying diagnosis is unknown Improved understanding of the role of overactive bladder syndrome and storage symptoms in the etiology of LUTS in men has led to a paradigm shift away from the disorder being equated with prostatic disease or bladder outlet obstruction The aims of medical therapy for LUTS in men should be to improve the bothersome symptoms and/or reduce progression of the disease The availability of effective medical treatments for LUTS has led to a dramatic decline in the number of prostatectomies that are performed Enhanced understanding of the underlying causes of male LUTS has led to an interest in the role of anticholinergics and phosphodiesterase type-5 inhibitors in the management of LUTS Combination therapy might optimize medical management but much further research is needed to develop appropriate regimens, and cost-effectiveness and the cumulative adverse affects must also be borne in mind</description><identifier>ISSN: 1743-4270</identifier><identifier>ISSN: 1759-4812</identifier><identifier>EISSN: 1743-4289</identifier><identifier>EISSN: 1759-4820</identifier><identifier>DOI: 10.1038/ncpuro1060</identifier><identifier>PMID: 18301417</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>5-alpha Reductase Inhibitors ; Adrenergic alpha-Antagonists - therapeutic use ; Bladder ; Care and treatment ; Cholinergic Antagonists - therapeutic use ; Drug therapy ; Drug Therapy, Combination ; Enzyme Inhibitors - therapeutic use ; Health aspects ; Humans ; Hyperplasia ; Male ; Medicine ; Medicine &amp; Public Health ; Phytotherapy ; Prostate ; Prostatectomy ; Prostatic Hyperplasia - complications ; Prostatic Hyperplasia - drug therapy ; review-article ; Risk Factors ; Urinary Bladder Neck Obstruction - drug therapy ; Urinary Bladder Neck Obstruction - etiology ; Urinary retention ; Urinary tract infections ; Urination Disorders - drug therapy ; Urination Disorders - etiology ; Urogenital system ; Urology</subject><ispartof>Nature clinical practice urology, 2008-04, Vol.5 (4), p.211-219</ispartof><rights>Springer Nature Limited 2008</rights><rights>COPYRIGHT 2008 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Apr 2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c441t-8b79b9f1e6dd80a4c0c4ed66baef0dd889cdcb36b0b992dab30d1d0e694828e13</citedby><cites>FETCH-LOGICAL-c441t-8b79b9f1e6dd80a4c0c4ed66baef0dd889cdcb36b0b992dab30d1d0e694828e13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2727,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18301417$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chapple, Christopher R</creatorcontrib><creatorcontrib>Patel, Anand K</creatorcontrib><title>Medical management of lower urinary tract symptoms in men: current treatment and future approaches</title><title>Nature clinical practice urology</title><addtitle>Nat Rev Urol</addtitle><addtitle>Nat Clin Pract Urol</addtitle><description>Men with lower urinary tract symptoms frequently do not seek medical advice. For those who do, the traditional view of a solely prostatic origin might hinder management, since growing evidence suggests an important role for nonprostatic causes. This Review clarifies terminology for symptoms and causes and presents an overview of the available medical therapies. Lower urinary tract symptoms (LUTS) are extremely common in men and, in addition to causing considerable bother, can lead to the development of complications, such as acute urinary retention. Over the past couple of decades, developments in the medical management of LUTS in men have led to a substantial decline in the number of surgical procedures being performed to treat associated disorders, such as prostatectomy for benign prostatic enlargement. In this Review we summarize the available treatments and discuss the latest data on the use of anticholinergics and phosphodiesterase type-5 inhibitors for this indication. We also review the various combinations of medical therapies that have been reported in the literature to optimize the management of LUTS in men. In addition, there is a growing realization that LUTS in men are not synonymous with prostatic disease, and in many patients overactive bladder syndrome is the cause or a component of the LUTS experienced; we have, therefore, taken the opportunity to try to clarify the terminology used in LUTS in men, since there is the potential for considerable confusion with the terms that are currently in common usage in any discussion of this disorder. Key Points Although terminology regarding lower urinary tract symptoms (LUTS) in men and their underlying disorders has evolved, it remains confusing, and terms describing the nature of the LUTS (voiding or storage) might be more appropriate, particularly when the underlying diagnosis is unknown Improved understanding of the role of overactive bladder syndrome and storage symptoms in the etiology of LUTS in men has led to a paradigm shift away from the disorder being equated with prostatic disease or bladder outlet obstruction The aims of medical therapy for LUTS in men should be to improve the bothersome symptoms and/or reduce progression of the disease The availability of effective medical treatments for LUTS has led to a dramatic decline in the number of prostatectomies that are performed Enhanced understanding of the underlying causes of male LUTS has led to an interest in the role of anticholinergics and phosphodiesterase type-5 inhibitors in the management of LUTS Combination therapy might optimize medical management but much further research is needed to develop appropriate regimens, and cost-effectiveness and the cumulative adverse affects must also be borne in mind</description><subject>5-alpha Reductase Inhibitors</subject><subject>Adrenergic alpha-Antagonists - therapeutic use</subject><subject>Bladder</subject><subject>Care and treatment</subject><subject>Cholinergic Antagonists - therapeutic use</subject><subject>Drug therapy</subject><subject>Drug Therapy, Combination</subject><subject>Enzyme Inhibitors - therapeutic use</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Hyperplasia</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Phytotherapy</subject><subject>Prostate</subject><subject>Prostatectomy</subject><subject>Prostatic Hyperplasia - complications</subject><subject>Prostatic Hyperplasia - drug therapy</subject><subject>review-article</subject><subject>Risk Factors</subject><subject>Urinary Bladder Neck Obstruction - drug therapy</subject><subject>Urinary Bladder Neck Obstruction - etiology</subject><subject>Urinary retention</subject><subject>Urinary tract infections</subject><subject>Urination Disorders - drug therapy</subject><subject>Urination Disorders - etiology</subject><subject>Urogenital system</subject><subject>Urology</subject><issn>1743-4270</issn><issn>1759-4812</issn><issn>1743-4289</issn><issn>1759-4820</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptkUtr3DAUhUVpyavZ9AcUQaGLhEkkS7Hk7EJokkJKN-la6HE9dbAlVw9K_n3lzpBMS9BC4uo7R1f3IPSBkjNKmDz3di4xUNKSN-iACs5WvJHd2-ezIPvoMKVHQpgQnO6hfSoZoZyKA2S-gRusHvGkvV7DBD7j0OMx_IaISxy8jk84R20zTk_TnMOU8OBx5S6xLTEufI6g81-l9g73JZcIWM9zDNr-hPQevev1mOB4ux-hHzdfHq7vVvffb79eX92vLOc0r6QRnel6Cq1zkmhuieXg2tZo6Ektyc46a1hriOm6xmnDiKOOQNtx2Uig7Ah93vjWh38VSFlNQ7IwjtpDKEkJwkXDGK_gp__Ax1Cir70pKmQnZXNBdqi1HkENvg_LGBZLdUVle0GFaFmlzl6h6nIwDTZ46Ida_0dwshHYGFKK0Ks5DlOdsqJELXGqlzgr_HHbaTETuBd0m18FTjdAqld-DXHnK6_Z4Q3t9ZLRs90O8gf6Nbai</recordid><startdate>20080401</startdate><enddate>20080401</enddate><creator>Chapple, Christopher R</creator><creator>Patel, Anand K</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20080401</creationdate><title>Medical management of lower urinary tract symptoms in men: current treatment and future approaches</title><author>Chapple, Christopher R ; Patel, Anand K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c441t-8b79b9f1e6dd80a4c0c4ed66baef0dd889cdcb36b0b992dab30d1d0e694828e13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>5-alpha Reductase Inhibitors</topic><topic>Adrenergic alpha-Antagonists - therapeutic use</topic><topic>Bladder</topic><topic>Care and treatment</topic><topic>Cholinergic Antagonists - therapeutic use</topic><topic>Drug therapy</topic><topic>Drug Therapy, Combination</topic><topic>Enzyme Inhibitors - therapeutic use</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Hyperplasia</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Phytotherapy</topic><topic>Prostate</topic><topic>Prostatectomy</topic><topic>Prostatic Hyperplasia - complications</topic><topic>Prostatic Hyperplasia - drug therapy</topic><topic>review-article</topic><topic>Risk Factors</topic><topic>Urinary Bladder Neck Obstruction - drug therapy</topic><topic>Urinary Bladder Neck Obstruction - etiology</topic><topic>Urinary retention</topic><topic>Urinary tract infections</topic><topic>Urination Disorders - drug therapy</topic><topic>Urination Disorders - etiology</topic><topic>Urogenital system</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chapple, Christopher R</creatorcontrib><creatorcontrib>Patel, Anand K</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Nature clinical practice urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chapple, Christopher R</au><au>Patel, Anand K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Medical management of lower urinary tract symptoms in men: current treatment and future approaches</atitle><jtitle>Nature clinical practice urology</jtitle><stitle>Nat Rev Urol</stitle><addtitle>Nat Clin Pract Urol</addtitle><date>2008-04-01</date><risdate>2008</risdate><volume>5</volume><issue>4</issue><spage>211</spage><epage>219</epage><pages>211-219</pages><issn>1743-4270</issn><issn>1759-4812</issn><eissn>1743-4289</eissn><eissn>1759-4820</eissn><abstract>Men with lower urinary tract symptoms frequently do not seek medical advice. For those who do, the traditional view of a solely prostatic origin might hinder management, since growing evidence suggests an important role for nonprostatic causes. This Review clarifies terminology for symptoms and causes and presents an overview of the available medical therapies. Lower urinary tract symptoms (LUTS) are extremely common in men and, in addition to causing considerable bother, can lead to the development of complications, such as acute urinary retention. Over the past couple of decades, developments in the medical management of LUTS in men have led to a substantial decline in the number of surgical procedures being performed to treat associated disorders, such as prostatectomy for benign prostatic enlargement. In this Review we summarize the available treatments and discuss the latest data on the use of anticholinergics and phosphodiesterase type-5 inhibitors for this indication. We also review the various combinations of medical therapies that have been reported in the literature to optimize the management of LUTS in men. In addition, there is a growing realization that LUTS in men are not synonymous with prostatic disease, and in many patients overactive bladder syndrome is the cause or a component of the LUTS experienced; we have, therefore, taken the opportunity to try to clarify the terminology used in LUTS in men, since there is the potential for considerable confusion with the terms that are currently in common usage in any discussion of this disorder. Key Points Although terminology regarding lower urinary tract symptoms (LUTS) in men and their underlying disorders has evolved, it remains confusing, and terms describing the nature of the LUTS (voiding or storage) might be more appropriate, particularly when the underlying diagnosis is unknown Improved understanding of the role of overactive bladder syndrome and storage symptoms in the etiology of LUTS in men has led to a paradigm shift away from the disorder being equated with prostatic disease or bladder outlet obstruction The aims of medical therapy for LUTS in men should be to improve the bothersome symptoms and/or reduce progression of the disease The availability of effective medical treatments for LUTS has led to a dramatic decline in the number of prostatectomies that are performed Enhanced understanding of the underlying causes of male LUTS has led to an interest in the role of anticholinergics and phosphodiesterase type-5 inhibitors in the management of LUTS Combination therapy might optimize medical management but much further research is needed to develop appropriate regimens, and cost-effectiveness and the cumulative adverse affects must also be borne in mind</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>18301417</pmid><doi>10.1038/ncpuro1060</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1743-4270
ispartof Nature clinical practice urology, 2008-04, Vol.5 (4), p.211-219
issn 1743-4270
1759-4812
1743-4289
1759-4820
language eng
recordid cdi_proquest_miscellaneous_70472334
source MEDLINE; Nature; Alma/SFX Local Collection
subjects 5-alpha Reductase Inhibitors
Adrenergic alpha-Antagonists - therapeutic use
Bladder
Care and treatment
Cholinergic Antagonists - therapeutic use
Drug therapy
Drug Therapy, Combination
Enzyme Inhibitors - therapeutic use
Health aspects
Humans
Hyperplasia
Male
Medicine
Medicine & Public Health
Phytotherapy
Prostate
Prostatectomy
Prostatic Hyperplasia - complications
Prostatic Hyperplasia - drug therapy
review-article
Risk Factors
Urinary Bladder Neck Obstruction - drug therapy
Urinary Bladder Neck Obstruction - etiology
Urinary retention
Urinary tract infections
Urination Disorders - drug therapy
Urination Disorders - etiology
Urogenital system
Urology
title Medical management of lower urinary tract symptoms in men: current treatment and future approaches
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T06%3A50%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Medical%20management%20of%20lower%20urinary%20tract%20symptoms%20in%20men:%20current%20treatment%20and%20future%20approaches&rft.jtitle=Nature%20clinical%20practice%20urology&rft.au=Chapple,%20Christopher%20R&rft.date=2008-04-01&rft.volume=5&rft.issue=4&rft.spage=211&rft.epage=219&rft.pages=211-219&rft.issn=1743-4270&rft.eissn=1743-4289&rft_id=info:doi/10.1038/ncpuro1060&rft_dat=%3Cgale_proqu%3EA186517763%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1789882504&rft_id=info:pmid/18301417&rft_galeid=A186517763&rfr_iscdi=true